Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

One-Time gene shot may slash eye needles for Diabetes-Related vision loss

NCT ID NCT05930561

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 33 times

Summary

This study tests a gene therapy called 4D-150 for people with diabetic macular edema, a condition that causes vision loss due to diabetes. The goal is to see if a single injection of the gene therapy can reduce the need for frequent eye injections over two years. About 72 adults who respond well to standard treatment will participate, and the study compares the gene therapy to a control group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Austin Clinical Research

    Austin, Texas, 78750, United States

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland, 21740, United States

  • Emanuelli Research and Development Center

    Arecibo, X00612, Puerto Rico

  • Erie Retina Research

    Erie, Pennsylvania, 16507, United States

  • Piedmont Eye Center

    Lynchburg, Virginia, 24502, United States

  • Verum Research, LLC

    Eugene, Oregon, 97401, United States

Conditions

Explore the condition pages connected to this study.